I thought I would highlight some of the reasons I think Neu is...

I thought I would highlight some of the reasons I think Neu is materially undervalued .
1.Company is valued by the market as of yesterday at $2.06 billion .
2. Cash on hand at the 30th of June 2024 $213 million .Earning approx $10 mill a year
3.Royalties of $13 mill payable in q3 2024.
4.Franking credits of $34 mill .
5.Estimated royalties and milestones in next 12 months approx $135 mill .
6.Priority review voucher sale of $50 mill likely payable in next 12 months .
7.Potential dividend imputation scheme to be implemented with large franking credits of $34 mill.
8.Potential share buyback (often once the buyback is announced the shorters start to get very nervous)
9.Potential for another Priority review voucher for NNZ2591 potentially worth $150 mill .
10.Daybue ROW revenue about to start .
11.Acadia no doubt has been in touch with Neuren to discuss NNZ2591 for Retts and Fragile x
12.NNZ2591 successful trials for 3 indications.
13.Analyst valuations prior to yesterdays Angelmans update between $25 and $30 .
14.FDA discussions in September and likely letter from them in October re first Phase 3 trial for NNZ2591 .
15.Institutions now own very close to 50% as small retail investors have been selling .
16.Other major shareholders own about 20% .so a takeover is possible but has to be at an acceptable figure to the NEU board .